eli lilly retatrutide study Lilly's triple agonist hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Novo Duopoly Lilly orforglipron oral GLP-1 phase

Nobut they make both easier by reducing hunger and increasing satiety.

The real fat loss builds over the following weeks and months

In this context, the data currently available on tirzepatide, showing its efficacy in glycemic control to the extent that a considerable percentage of patients achieve glucose levels indicative of diabetes remission [3, 59], as well as its high effectiveness in weight management, are promising regarding its future use in clinical practice

The STEP clinical trial program demonstrated that targeting the GLP 1 receptor alone could produce meaningful and sustained weight loss in most patients